WuXi AppTec Co. Ltd (WX8) - Cash Flow Conversion Efficiency
Based on the latest financial reports, WuXi AppTec Co. Ltd (WX8) has a cash flow conversion efficiency ratio of 0.061x as of March 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€3.03 Billion ≈ $3.54 Billion USD) by net assets (€49.83 Billion ≈ $58.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See WuXi AppTec Co. Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
WuXi AppTec Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how WuXi AppTec Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
WuXi AppTec Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of WuXi AppTec Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NMDC Limited
NSE:NMDC
|
0.094x |
|
ALIB.HL.INF.TEC.UNSP.ADR
F:TWYA
|
N/A |
|
Meridian Energy Ltd
AU:MEZ
|
0.038x |
|
China Greatwall Computer Shenzhen Co Ltd
SHE:000066
|
-0.002x |
|
Capstone Mining Corp
TO:CS
|
0.029x |
|
Companhia Paranaense de Energia - COPEL
NYSE:ELPC
|
0.023x |
|
Enersys
NYSE:ENS
|
0.097x |
|
Vietnam Technological And Commercial Joint Stock Bank
VN:TCB
|
-0.065x |
Annual Cash Flow Conversion Efficiency for WuXi AppTec Co. Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of WuXi AppTec Co. Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see WuXi AppTec Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €80.25 Billion ≈ $93.82 Billion |
€17.20 Billion ≈ $20.11 Billion |
0.214x | +2.10% |
| 2024-12-31 | €59.09 Billion ≈ $69.08 Billion |
€12.41 Billion ≈ $14.50 Billion |
0.210x | -12.92% |
| 2023-12-31 | €55.52 Billion ≈ $64.91 Billion |
€13.39 Billion ≈ $15.65 Billion |
0.241x | +6.59% |
| 2022-12-31 | €46.93 Billion ≈ $54.86 Billion |
€10.62 Billion ≈ $12.41 Billion |
0.226x | +91.05% |
| 2021-12-31 | €38.76 Billion ≈ $45.31 Billion |
€4.59 Billion ≈ $5.37 Billion |
0.118x | -2.50% |
| 2020-12-31 | €32.72 Billion ≈ $38.25 Billion |
€3.97 Billion ≈ $4.65 Billion |
0.121x | -27.49% |
| 2019-12-31 | €17.41 Billion ≈ $20.35 Billion |
€2.92 Billion ≈ $3.41 Billion |
0.167x | +85.47% |
| 2018-12-31 | €18.17 Billion ≈ $21.24 Billion |
€1.64 Billion ≈ $1.92 Billion |
0.090x | -66.08% |
| 2017-12-31 | €6.74 Billion ≈ $7.88 Billion |
€1.79 Billion ≈ $2.10 Billion |
0.266x | -8.14% |
| 2016-12-31 | €6.06 Billion ≈ $7.09 Billion |
€1.76 Billion ≈ $2.05 Billion |
0.290x | -- |
About WuXi AppTec Co. Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more